Literature DB >> 3401594

Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro.

K Iwato1, M Kawano, H Asaoku, O Tanabe, H Tanaka, A Kuramoto.   

Abstract

Human myeloma cells were purified from bone marrow aspirates from patients with multiple myeloma (MM) by Percoll discontinuous density-gradient centrifugation, E rosette formation and treatment with antimyelomonocytic antibody (Leu M1), plus complement. Thus, the purified cell fraction consisted of greater than 90% myeloma cells, even when as little as 15% myeloma cells were contained in bone marrow mononuclear cell fraction, determined by morphological and immunologic examinations. With highly purified myeloma cells from 29 patients with IgG type MM, biologic characteristics such as spontaneous proliferation (3H-TdR uptake) and M-protein secretion rate in vitro were evaluated. Both activities varied among patients within stage I and III, and a 3H-TdR uptake of 255-24, 132 cpm/4 x 10(4) cells, and an M-protein secretion rate of 9 to 72 pg/cell/day, respectively, were recorded. However, in each patient, there was no correlation between 3H-TdR uptake and M-protein secretion rate. These results thus suggest that 3H-TdR uptake and M-protein secretion rate of highly purified myeloma cells are independent biologic parameters, not associated with the clinical stages, and the purification of myeloma cells we describe can contribute to further studies on the biologic characteristics and to understanding of the pathophysiology involved in MM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401594

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.

Authors:  E J Ahsmann; R J Benschop; T D de Gruyl; J A Faber; H M Lokhorst; A C Bloem
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

2.  Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.

Authors:  N Nishimoto; A Ogata; Y Shima; Y Tani; H Ogawa; M Nakagawa; H Sugiyama; K Yoshizaki; T Kishimoto
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

3.  Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.

Authors:  H Goto; C Shimazaki; T Tatsumi; N Yamagata; T Hirata; E Ashihara; N Oku; T Inaba; N Fujita; Y Koishihara
Journal:  Jpn J Cancer Res       Date:  1994-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.